Navigation Links
Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
Date:6/23/2011

ng minimal impact on the other monoamines thereby reducing the likelihood of "off target" side effects.NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.

NBI-98854 may be useful in other disorders such as Huntington's chorea, schizophrenia, Tourette's syndrome, and tardive dystonia.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contra
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
2. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
3. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
4. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
5. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
6. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
7. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
9. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
10. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
11. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 /PRNewswire/ - Aptose Biosciences Inc. ... developing new therapeutics that target the underlying mechanisms of ... Administration (FDA) has granted the company orphan drug designation ... (AML). APTO-253, a first-in-class inducer of the KLF4 gene, ... Ib clinical trial in patients with AML, high-risk myelodysplastic ...
(Date:6/2/2015)... NEW YORK , Jun. 02, 2015 /PRNewswire/ ... "Company"), a diversified life sciences company with interests ... a proprietary synthetic biology platform technology, today announced ... to Typenex Co-Investment, LLC ("Typenex") in exchange for ... January 16, 2015, the Company and Typenex entered ...
(Date:6/2/2015)... Meet ARGUS, The World,s First ... Read People. Analyze emotions and predict actions. Explore a ... very first Responsive-RPG: "The Eye: Genesis".      ... , , https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 ... inner feelings - and those of others. Being able ...
(Date:6/2/2015)... , June 2, 2015   Hospira, Inc. ... biosimilars, today announced that its partner, Celltrion – a global ... the National Health Surveillance Agency in Brazil ... monoclonal antibody approved for use in Brazil ... Hospira also markets and sells biosimilar infliximab in 26 ...
Breaking Biology Technology:Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 4ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5
... Technology (QUT) researchers have developed new technology capable ... aiding clean-up efforts following nuclear disasters. The ... to clean up millions of tonnes of water ... the concentrated waste. Professor Huai-Yong Zhu from ...
... Cadence Pharmaceuticals, Inc. (NASDAQ: CADX ), a ... products principally for use in the hospital setting, today ... will present the company,s corporate overview on Wednesday, November ... during the Credit Suisse Healthcare Conference at the Arizona ...
... Axia Value Chain, a market leader in business ... of their Life Sciences and Health Care Practice Group. ... with global clients in the Health Care and Life ... services, practice development, and service offerings concentrating on alignment ...
Cached Biology Technology:Technology makes storing radioactive waste safer 2Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice 2
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... the behaviors of individual cells and the functions and ... the complex interactions of cell clusters have not been ... Emergent Behaviors of Integrated Cellular Systems (EBICS) Center to ... the University of Illinois at Urbana-Champaign, and the Georgia ...
... From how massive humpbacks glide through the sea with ease ... Harvard have excavated the equations behind a variety of complex ... Michael Brenner, working closely with a team of Harvard evolutionary ... most famous icon of evolution: the beaks of Darwin,s finches. ...
... industrialized countries have easy access to healthy food and nutritional ... because new research from Tel Aviv University suggests that magnesium, ... even more critical than previously thought for the neurons of ... MIT, the research started as a part of a post-doctoral ...
Cached Biology News:$25M NSF center established to investigate the creation of biological machines 2$25M NSF center established to investigate the creation of biological machines 3$25M NSF center established to investigate the creation of biological machines 4Simple math explains dramatic beak shape variation in Darwin's finches 2Simple math explains dramatic beak shape variation in Darwin's finches 3Remember magnesium if you want to remember 2
... derived from frozen embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 7 ... are large (3-5 mm in diameter) in ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
... from Paraffin embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 5 microns ... large (3-5mm in diameter) in comparison to ...
... Engine Opticon real-time PCR detection system uses ... excitation (450-495 nm) and a photomultiplier tube ... system is built on an DNA Engine ... gradient feature. This item includes the thermal ...
Biology Products: